Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Researchers Discover First Treatment to Improve Survival in Rare Heart Condition

By European Society of Cardiology | August 28, 2018

Tafamidis is the first treatment to improve survival and reduce hospitalizations in a rare heart condition called transthyretin amyloid cardiomyopathy, according to late breaking research presented in a Hot Line Session at ESC Congress 20181 and published in the New England Journal of Medicine.

Professor Claudio Rapezzi, principal investigator, University of Bologna, Italy, said: “There are no medications specifically approved for the treatment of transthyretin amyloid cardiomyopathy. Tafamidis improved survival and quality of life, and reduced hospitalisations, indicating that it could be an effective therapy for these patients. A submission to the regulatory authorities for marketing approval is in process as a consequence of this study.”

Transthyretin amyloid cardiomyopathy is a rare, progressive, fatal disease. The hereditary form is caused by mutations in the TTR gene and typically presents in 50-70 year-olds, while the acquired (wild-type) form presents in 60-80 year-olds. The disease is caused when the transport protein, transthyretin, becomes unstable and misfolds, leading to the formation of amyloid, which is deposited in the heart. This causes the heart muscle to become stiff and results in heart failure.

Patients have debilitating symptoms common to heart failure, such as shortness of breath, fatigue, orthostatic hypotension, and syncope, leading to frailty and poorer quality of life. Patients survive an average of three to five years after diagnosis. There are no approved drugs to improve survival, and therapy is limited to managing symptoms.

Tafamidis stabilises transthyretin, preventing misfolding and the formation of amyloid. Treatment with this therapy delays neurologic progression in transthyretin familial amyloid polyneuropathy, a similar condition in which amyloid is deposited in the nerves after transthyretin misfolding. The drug is approved for this condition in the EU.

The medicine has not been approved for the treatment of transthyretin amyloid cardiomyopathy, but has orphan drug designation from the European Medicines Agency (EMA) and Fast Track designation from the US Food and Drug Administration (FDA).

The ATTR-ACT trial assessed the efficacy and safety of tafamidis in patients with hereditary and acquired transthyretin amyloid cardiomyopathy. The trial enrolled 441 patients aged 18-90 years from 48 centres in 13 countries. Patients were randomised in a 2:1:2 ratio to tafamidis 80 mg, tafamidis 20 mg, or placebo – all taken orally, once a day, for 30 months.

The primary endpoint was the hierarchical combination of all-cause death and cardiovascular-related hospitalisations from baseline to 30 months. The two tafamidis groups were combined and compared with the placebo group. Secondary outcomes included the change from baseline to 30 months in exercise capacity (assessed with the six-minute walk test) and in health-related quality of life (assessed using the Kansas City Cardiomyopathy Questionnaire).

A total of 264 patients received the drug and 177 received placebo. Tafamidis significantly reduced death and cardiovascular-related hospitalisation compared to placebo (p=0.0006). During the 30-month follow-up, 78 (29.5%) patients receiving the medicine died compared to 76 (42.9%) receiving placebo – this included patients who underwent heart transplant or received a cardiac mechanical assist device as these were classified as death in the analysis.3 Rates of cardiovascular-related hospitalisations were 52.3% and 60.5% in the tafamidis and placebo groups, respectively.

The therapy also reduced the decline in six-minute walk distance and quality of life compared with placebo. The incidence of individual adverse events were similar or fewer with drug treatment. Discontinuations of study drug due to treatment-related adverse events were less common with tafamidis than placebo.

Professor Rapezzi said: “ATTR-ACT is the largest randomised clinical trial in patients with transthyretin amyloid cardiomyopathy to date. The trial showed that tafamidis is superior to placebo in reducing the risk of death and cardiovascular-related hospitalisations. Tafamidis also reduced the decline in functional capacity and quality of life and had a favourable safety profile in these patients.”

He concluded: “These findings provide strong evidence that tafamidis is an effective therapy for patients with transthyretin amyloid cardiomyopathy and can modify the natural history of this disease.”

SOURCE: European Society of Cardiology


Filed Under: Orphan Drugs

 

Related Articles Read More >

Sanofi logo
Rilzabrutinib on track for regulatory filing after ITP trial win
Amylyx
HELIOS trial Q&A: Amylyx Pharmaceuticals’ AMX0035 as a potential treatment for Wolfram syndrome
Bristol Myers Squibb
FDA approves Bristol-Myers Squibb immunotherapy for gastric cancer
eye
Investigational drug gives sight to patient with inherited form of blindness 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE